Skip to content

Opko Health OPK Free cash flow

Free cash flow at other companies

HRO
HarrowHROW
-$9.19M-147%
Precigen logo
PrecigenPGEN
-$44.09M-160%
Immunome logo
ImmunomeIMNM
-$61.64M-8.7%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-$198M-18.6%
Abbott logo
AbbottABT
$916M-1.8%
Quest Diagnostics logo
Quest DiagnosticsDGX

Other financials

Income statement

See full
Revenue$124.2M-17.2%
Gross profit$45.8M+7.4%
Operating income-$51.0M+24.0%
Net income-$54.8M+18.9%
EPS (diluted)-$0.07+30.0%

Balance sheet

See full
Cash & equivalents$40.6M-62.5%
Total debt$52.8M-4.2%
Total equity$1.2B-8.2%
Total assets$1.9B-12.8%

Cash flow

See full
Operating cash flow-$19.3M+44.1%
CapEx$1.8M-42.6%

Valuation

See full
Market cap$1.13B-22.4%
P/S1.9×-0.2×

Profitability

See full
Gross margin36%+4.2pp
Operating margin-17.4%-5.6pp
Net margin-36.6%-44.8pp
FCF margin-30%+0.1pp

Returns & leverage

See full
Return on equity-16.9%-21.7pp
Debt / equity0.0×
Current ratio3.6×+1.1×

Where this comes from

Calculated from Opko Health’s reported figures.

The official record: Opko Health’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Opko Health's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Opko Health's free cash flow?
Opko Health (OPK) reported free cash flow of -$21.14M in Q1 2026.
How has Opko Health's free cash flow changed year-over-year?
Opko Health's free cash flow increased by 44.0% year-over-year, from -$37.75M to -$21.14M.
What is the long-term trend for Opko Health's free cash flow?
Over 2 years (2022 to 2025), Opko Health's free cash flow has grown at a 26.2% compound annual growth rate (CAGR), from -$119.77M to -$190.82M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.